Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Cascade Microtech Sees One Insider Buy

Cascade Microtech, insider buy: Cascade Microtech, Inc. (NASDAQ:CSCD) experienced insider trading this Monday, when Steven Harris acquired 6,294 shares of common stock at $3.11 per share. He did so exercising his stock options, which he receives as compensation due to his position as Executive Vice President of Cascade Microtech. This transaction brought the number of securities owned by Harris to 55,139 shares, or approximately $554,146 worth of stock. Cascade is trading near its 52-week high of $10.13, yet the stock has been growing continuously over the past few weeks, with no decline in share value expected anytime soon.


Unlike other insider trades, the purchase executed by Harris was not made in order to hold onto Cascade stock. Instead, the Executive Vice President sold off the discounted shares he acquired at $10 each, at a profit of over 300%, on the open market the same day.

There are three strong hedge funds in Cascade, each holding a different position in terms of size. Becker Drapkin Management, of Matthew Drapkin and Steven R. Becker, holds 1,048,712 shares of the company. This represents a total sum of approximately $ 10,539,555 and makes up around 5.02% of the hedge fund’s equity portfolio. Renaissance Technologies also holds an important stake in the firm, with 278,300 shares, whereas Algert Coldiron Investors has a minor position of 25,517 shares, or $256,445.

Cascade is responsible for the designing, developing and manufacturing of advanced wafer probing and test socket solutions used for the electrical measurement and the testing of high performance chips. The firm has an solid long-term revenue growth rate of 25%, no recorded debt, and very high levels of free cash flow. While trading at just 23.7 times its trailing earnings, the stock is available at a minor price premium of 1.3% to industry averages.

Disclosure: Pablo Erbar holds no position in any stocks mentioned.

Recommended Reading:

A Verastem Board Member Bought in at $11.53

Brandywine Realty’s Howard Sipzner Takes Another Sip of Stock

Western Asset Mortgage Capital’s CEO is Buying

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!